Table 2 2023 ASCO updates from clinical trials of CD20 × CD3 bispecific antibodies for lymphoma therapy
From: CD20 × CD3 bispecific antibodies for lymphoma therapy: latest updates from ASCO 2023 annual meeting
Regimen | Epcor | Glofit | Epcor + R-CHOP | Glofit + Pola-R-CHP | Epcor + R2 |
|---|---|---|---|---|---|
Lymphoma | R/R LBCL | R/R LBCL | 1L high-risk DLBCL | 1L DLBCL | R/R FL |
Pts | 157 | 154 | 47 | 24 | 109 |
mFU | 20 m | 20.1 m | 11.5 m | 5.1 m | 8.8 m |
(range: 0.3+–28.2) | (range: 0–32) | (range: 0.8–15.5) | (range: 3–8) | (range: 1.2–18.5) | |
ORR | 63.1% | 59% | 100% | 100% | 97% |
CR/CMR | CR: 39.5% | CR: 38% | CMR: 76% | CMR: 76.5% | CMR: 86% |
mDoCR | 20.8 m | 24.1 m (95% CI 19.8–NR) | NR | NR | NR |
PFS | 87.2% at 1 year in pts with a CR | 80% at 1 year in pts with a CR at EOT | NR | NR | NR |
OS | mOS:18.5 m (95% CI 11.7–NR) | 41% (18-m) (95% CI 32.1–49.3) | NR | NR | NR |
CRS | 51% | 64% | 60% | 13% | 48% |
G1–2 | 48% | 60% | 57% | 13% | 46% |
G ≥ 3 | 3% | 4% | 2% | 0 | 2% |
NAE/ICANS | ICANS: 6% | NA | ICANS: 2% | NAE: 46% | ICANS: 2% |
G1–2 | 6% | 2% | 42% | 2% | |
G ≥ 3 | 1% | 0 | 4% | 0% | |
Clinical trial number | NCT03625037 | NCT03075696 | NCT04663347 | NCT03467373 | NCT04663347 |
References | [10] | [4] | [11] | [3] | [12] |